Alexander Tenenbaum

Summary

Affiliation: Tel Aviv University
Country: Israel

Publications

  1. Tenenbaum A, Fisman E. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012;11:125 pubmed publisher
    ..Fibrates currently constitute an indispensable part of the modern anti-dyslipidemic arsenal for patients with atherogenic dyslipidemia. ..
  2. Tenenbaum A, Fisman E. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?. Cardiovasc Diabetol. 2012;11:140 pubmed publisher
    ....
  3. request reprint
    Tenenbaum A, Motro M, Fisman E, Schwammenthal E, Adler Y, Goldenberg I, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197-202 pubmed
    ..2-year follow-up period...
  4. request reprint
    Tenenbaum A, Motro M, Fisman E, Adler Y, Shemesh J, Tanne D, et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005;26:2032-8 pubmed
    ..To assess the effect of fibric acid derivative bezafibrate on incidence of type 2 diabetes in obese patients over a median 6.3 years follow-up period...
  5. Tenenbaum A, Fisman E, Motro M, Adler Y. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?. Adv Cardiol. 2008;45:127-53 pubmed publisher
    ....
  6. Tenenbaum A, Boyko V, Fisman E, Goldenberg I, Adler Y, Feinberg M, et al. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?. Cardiovasc Diabetol. 2008;7:18 pubmed publisher
    ..Therefore, we proposed to investigate a possible preventive effect of bezafibrate on the development of colon cancer in patients with coronary artery disease during a 6-year follow-up...

Detail Information

Publications6

  1. Tenenbaum A, Fisman E. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012;11:125 pubmed publisher
    ..Fibrates currently constitute an indispensable part of the modern anti-dyslipidemic arsenal for patients with atherogenic dyslipidemia. ..
  2. Tenenbaum A, Fisman E. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?. Cardiovasc Diabetol. 2012;11:140 pubmed publisher
    ....
  3. request reprint
    Tenenbaum A, Motro M, Fisman E, Schwammenthal E, Adler Y, Goldenberg I, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197-202 pubmed
    ..2-year follow-up period...
  4. request reprint
    Tenenbaum A, Motro M, Fisman E, Adler Y, Shemesh J, Tanne D, et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005;26:2032-8 pubmed
    ..To assess the effect of fibric acid derivative bezafibrate on incidence of type 2 diabetes in obese patients over a median 6.3 years follow-up period...
  5. Tenenbaum A, Fisman E, Motro M, Adler Y. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?. Adv Cardiol. 2008;45:127-53 pubmed publisher
    ....
  6. Tenenbaum A, Boyko V, Fisman E, Goldenberg I, Adler Y, Feinberg M, et al. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?. Cardiovasc Diabetol. 2008;7:18 pubmed publisher
    ..Therefore, we proposed to investigate a possible preventive effect of bezafibrate on the development of colon cancer in patients with coronary artery disease during a 6-year follow-up...